Outlook Therapeutics appoints Sukhtian as Chairman of the board of directors
Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian ...
PFG Investments LLC Grows Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)
PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...
Corcept Therapeutics Incorporated (NASDAQ:CORT) Receives $65.25 Consensus PT from Analysts
Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) has earned an average recommendation of “Buy” from the five ratings firms that are covering the company, Marketbeat reports. Five ...
Atossa Therapeutics: Strong Strategic Positioning and Patent Resilience Justifies Buy Rating
Atossa Therapeutics (ATOS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar ...
Hosted on MSN3d
Kazia Therapeutics launches trial of paxalisib/immunotherapy combination
Kazia Therapeutics (KZIA) is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib ...
TipRanks on MSN3d
Alterity Therapeutics announces ATH434 Phase 2 trial results
Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial in ...
Osta Therapeutics Strengthens Leadership Team with Two Industry Experts Supporting its Goal of Addressing Antibiotic Resistance
Osta Therapeutics, a biotechnology company developing smart drugs to fight antibiotic resistance, today announced the appointments of Dr. Gilles Courtemanche as Senior Scientific Advisor and Dr.